Attention deficit hyperactivity disorder: a short review

Aminder Gill*, Achal Bhatt

Windsor University School of Medicine, Brightons Estates, Cayon, St Kitts, West Indies

Received: 17 June 2016
Accepted: 12 July 2016

*Correspondence:
Dr. Aminder Gill,
E-mail: doctorid2016@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Attention deficit hyperactivity disorder (ADHD) is a common childhood psychiatric disorder with a prevalence of 4 to 8%. ADHD is characterized by hyperactivity, impulsiveness, and inappropriate inattentiveness. Though long considered a disease of childhood, studies have shown that a majority of cases persist in adulthood causing significant psychosocial impairment. Diagnosis is often based on clinical symptoms, and psychostimulants are mainstay in treatment of ADHD that are often complemented by psychotherapy and behavioural modifications.

Keywords: Hyperactivity, Impulsiveness, Stimulants, Inattention, Psychotherapy

INTRODUCTION

ADHD is one of the most common childhood psychiatric disorders. It is a neurodevelopmental disorder with a prevalence of 4-8% for ADHD in childhood. It has long been considered a disorder of childhood that resolve during adolescence with little or no continued percussion in adult life. However numerous studies of children with ADHD suggest that the disease persists during adulthood up to two-thirds of affected children.

Longitudinal follow up studies estimate the prevalence of adult ADHD (aADHD) ranges between 2.5 to 4.9 percent. Age and sex differences in prevalence rates of ADHD are routinely found in studies. Prevalence rates are higher in boys in the preschool group (8% in boys compared to 4% in girls). The prevalence decreases with age as adolescence sets in. Though symptoms of ADHD may appear to diminish during adulthood, this may not always be the case. In a follow up study of 119 boys of nineteen years of age with childhood onset ADHD, the symptoms levels decreased as they entered adolescence but about 90% of the study subjects still did not function well.

A study by World Health Organization (WHO) found several factors that predicted persistence of ADHD in adulthood. These predictors are severity of symptoms, other comorbidities, coexisting depression, social adversity and presence of ADHD in parents. ADHD also has a strong association with sleep disorders such as restless legs syndrome, circadian-rhythm sleep disorders, obstructive sleep apnea and peripheral limb movement disorder. A recent Australian study showed that 62% of children with ADHD had moderate or severe sleep problems and 22% took sleep medications during the 1-week observation period.

In children with ADHD other psychiatric comorbidities are common; up to 87% have at least one comorbidity, and 20% have three or more comorbid conditions. Other psychiatric disorders such as autism, bipolar disorder, obsessive compulsive disorder, and posttraumatic stress disorder occur concurrently with
ADHD and are associated with significant psychosocial impairment.

Increased rates of substance abuse, higher rates of anxiety & mood disorders, and high rates of traffic accidents have also been reported in patients with ADHD. Compared to controls, adults that suffer from ADHD have been reported to have more conflicts in their social and marital relationships. They also tend to underachieve in their careers, academics, and financial status despite adequate intellectual abilities. Longitudinally derived data in ADHD youth lifespan connotes that whereas symptoms of hyperactivity and impulsivity decay over time, the symptoms of inattention persist.

In support of this, data derived from a large group of adults with ADHD indicate that whereas approximately 50% of adults display clinically significant levels of hyperactive/impulsive symptomatology, 90% display prominent attentional symptomatology.

More specifically, adults with ADHD evidence a variety of core attentional symptoms, including poor attention and concentration, easy distractibility, frequent shifting of activities, daydreaming and forgetfulness; followed more distantly by impulsivity, impatience, boredom, fidgeting, and intrusiveness. ADHD adults are considered to experience executive function deficits, such as a reduced ability to attend, encode and manipulate information, and difficulties with organization and time management, as well as deficits in emotional regulation.

Pathophysiology, clinical features and treatment options

Data shows ADHD has a significant genetic component indicated by high heritability from parents. First-degree relatives of patients with ADHD have a high prevalence rate of 20-50%. There have been reports of increased strong risk of developing ADHD among offspring of adults with ADHD. In addition, strongly increased risks for ADHD (57%) among the offspring of adults with ADHD have been reported.

Numerous twin studies indicate an average heritability of about 76% suggesting that the strong familial influences on ADHD are mainly genetic. However studies of twin studies of self-rated ADHD symptoms among adult population report lower estimates of heritability of around 30-40%. There were no gender differences observed in the heritability estimates. Adoption studies show that ADHD is passed on only to biological relatives, which strongly suggests genetic factors playing a significant role causing high familial risk of the disease.

There has been a lot of interest as to why the disorder persists in some people and remits in others that can possibly identify new targets that will help prevent progression of the disorder into adult life. Jeffrey Halperin according to his hypothesis proposed that ADHD is linked to an early appearing and enduring subcortical dysfunction (weak arousal mechanisms), while symptom remission is dependent on the extent of maturational changes in executive control. He further suggested that the interaction between these two processes dictates the persistence or remission of symptoms of ADHD related to the emerging balance between subcortical and cortical function. This data was supported by a recent large study that obtained evidence that the same two processes account for eighty five percent and twelve percent respectively of the genetic influence of ADHD.

There are several genes implicated in the pathogenesis of ADHD. Genetic variants among the dopamine receptor genes D4 (DRD4) and D5 (DRD5) provide the most consistent findings supported by a large meta-analysis. Other genes implicated are dopamine transporter gene (DAT1), the serotonergic transporter (5-HTT), the synaptosomal associated protein, 25 kDa (SNAP-25), the dopamine beta-hydroxylase gene (DBH), and the serotonergic receptor (HTR1B). All these together account for roughly 3.2% of the variance in ADHD symptoms in children. Fronto-striatal circuitry in brain rich in dopaminergic activity has been strongly implicated in ADHD as supported by imaging studies using positron emission tomography (PET), and magnetic resonance imaging (MRI).

Environment also has a strong influence on ADHD. The disorder is best viewed as an interaction between genetic and environmental factors. Children with strong genetic predisposition are more likely to develop the disease if they are put in a correct environment often characterized by chaotic parenting. Studies have demonstrated improvements of symptoms in children with ADHD when parents have been taught alternative parenting skills. ADHD often affects the interactions of children with their parents.

Those with ADHD are usually more talkative, defiant, less cooperative, and less compliant. They find difficulty in managing day-to-day activities and cannot play or work independently of their mothers. In contrary to what is seen in normal mother-child interactions, the conflicts between them may get exacerbated when father gets involved in these interactions.

Exposure to environmental toxins like organohalide pesticides, herbicides, lead, arsenic, aluminum, mercury, fumigants, and a wide range of aromatic and aliphatic solvents have been linked to abnormalities in behavior, perception, cognition, and motor ability that can be subtle during early childhood but disabling over the long term. Diet is another environmental influence that can have adverse effects on symptoms of ADHD especially food additives, sugars and fatty acid deficiencies.

ADHD is characterised by symptoms such as hyperactivity, impulsivity and inappropriate level of...
inattention. These symptoms usually begin in childhood and leads to psychosocial impairment. Inattention is a key feature of the disorder causing inability to direct and maintain selective attention to motivationally relevant tasks.

Disorganization is frequently mentioned as one of the main indicators of inattention. Impulsivity refers to acting rashly without thinking about the consequences. Hyperactivity refers specifically to excessive/increased motor activity. As per the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria there are three subtypes of ADHD namely inattentive type, hyperactive -impulsive type and the combined type. A strong family history of ADHD was particularly present in persistent forms of ADHD. Stimulants like methylphenidate and dexamphetamine are first choice medications used in treatment of ADHD in children as well as adults based on extensive literature. Long lasting, extended release formulations are preferred because of compliance. Controlled studies have shown that they are effective in about 70% ADHD patients. Treatment with stimulants also improves related problems like mood swings, cognitive problems, low self-esteem, and cognitive problems. An European study done recently showed the effectiveness of methylphenidate over six months in the longest double blind placebo trial to date.

Stimulants are usually well tolerated and side effects are usually mild. Main side effects are fatigue, decreased appetite, palpitations, anxiety, difficulty sleeping, and dry mouth. They occasionally cause increase in blood pressure and tachycardia therefore a thorough assessment of the patient prior to treatment and close monitoring & follow up are often necessary. They are contraindicated in pregnancy.

Other relative contraindications include hypertrophic cardiomyopathy, angina, hyperthyroidism, glaucoma, and cardiac arrhythmias. Atomoxetine which is a non-stimulant can be a second line treatment. Controlled studies have shown efficacy of other agents like bupropion, tricyclic antidepressants, modafinil, and guanfacine. Pharmacotherapy alone is not sufficient in treatment of ADHD but should be combined with psychotherapy and behavioural modifications. Psychoeducation is often the initial step in the treatment plan, which involves educating the patient, their family members, and partners about the disease symptoms and impairment, frequent comorbidities, heritability and the treatment options. Coaching and cognitive behavioural therapy are often used in adjunct for treatment of ADHD.

CONCLUSION

ADHD is one of the most common childhood neurodevelopmental psychiatric disorders that causes significant psychosocial impairment and high comorbidity; if left untreated can lead to significant personal distress and high socioeconomic burden. Early diagnosis and treatment are imperative as it can significantly improve the quality of life of patients with ADHD as well as prevent further impairment. There are several pharmacotherapy agents available for the treatment of ADHD; mainly psychostimulants. Stimulants combined with psychotherapy and behavioural therapy provides an effective strategy for treatment of ADHD.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES

1. Faraone SV, Sergeant J, Gillberg C. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry. 2003;2:104-13.
2. Wood DR, Reimherr FW, Wender PH, Johnson GE. Diagnosis and treatment of minimal brain dysfunction in adults: a preliminary report. Arch Gen Psychiatry. 1976;33(12):1453-60.
3. Lara C, Fayad J, de Graaf R, Kessler RC, Aguilar-Gaxiola S, Angermeyer M, Demyttenaere K, de Girolamo G, Haro JM, Jin R, et al. Childhood predictors of adult attention-deficit/hyperactivity disorder: results from the World Health Organization World Mental Health Survey Initiative. Biol Psychiatry. 2009;65(1):46-54.
4. Lie N. Follow-ups of children with attention deficit hyperactivity disorder (ADHD). Review of literature. Acta Psychiatr Scand Suppl. 1992;368:1-40.
5. Gittelman R, Mannuzza S, Shenker R, Bonagura N. Hyperactive boys almost grown up. I. Psychiatric status. Arch Gen Psychiatry. 1985;42(10):937-47.
6. Weiss G, Hechtman L, Milroy T. Psychiatric status of hyperactives as adults: A controlled prospective 15-year follow-up of 63 hyperactive children. J Am Acad Child Psychiatry. 1985;24:211-20.
7. Mannuzza S, Klein RG, Addali KA. Young adult mental status of hyperactive boys and their brothers:
a prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1991;30(5):743-51.
8. Mannuzza S, Klein RG, Bessler A, Malloy P, et al. Adult outcome of hyperactive boys: Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry. 1993;50(7):565-76.
9. Barkley RA, Fischer M, Smallish L, Fletcher K. The persistence of attention- deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol. 2002;111(2):279-89.
10. Mannuzza S, Klein RG, Moulton JL. Persistence of Attention-Deficit/ Hyperactivity Disorder into adulthood: what have we learned from the prospective follow-up studies? J Atten Disord. 2003;7(2):93-100.
11. Rasmussen P, Gilberg C. Natural outcome of ADHD with developmental coordination disorder at age 22 years: a controlled, longitudinal, community-based study. Journal of the American Academy of Child and Adolescent Psychiatry. 2000;39(11):1424-31.
12. Simon V, Czobor P, Balint S, Meszaros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta- analysis. Br J Psychiatry 2009;194:204-11.
13. Breton J, Bergeron L, Valla JP, et al. Quebec children mental health survey: prevalence of DSM-III-R mental health disorders. J Child Psychol Psychiatry. 1999;40:375-84.
14. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry. 2000;157(5):816-8.
15. Efron D, Jarman F, Barker M. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics. 1997;100:662-6.
16. Hodgkins P, Setyawan J, Mitra D, Davis K, Quintero J, Fridman M, et al. Management of ADHD in children across Europe: patient demographics, physician characteristics and treatment patterns. Eur J Pediatr. 2013;172(7):895-906.
17. Rowland AS, Lesesne CA, Abramowitz AJ. The epidemiology of attention-deficit/hyperactivity disorder (ADHD): a public health view. Ment Retard Dev Disabil Res Rev. 2002;8:162-70.
18. Spruyt K, Gozal D. Sleep disturbances in children with attention-deficit/hyperactivity disorder. Expert Rev Neurother. 2011;11:565-77.
19. Weiss G, Hechtman LT. Hyperactive Children Grown Up. The Guilford Press; New York, NY, USA: 1986.
20. Mannuzza S, Klein RG, Bonagura N, Malloy P, Giampino TL, Addalli KA. Hyperactive boys almost grown up. V. Replication of psychiatric status. Arch Gen Psychiatry. 1991;48:77-83.
21. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M. Adult outcome of hyperactive boys: Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry. 1993;50:565-76.
22. Fischer M. Persistence of ADHD into adulthood: it depends on whom you ask. ADHD Rep. 1997;5(4):8-10.
23. Biederman J, Petty CR, Monuteaux MC, Fried R, Byrne D, Mirto T, et al. Adult psychiatric outcomes of girls with attention deficit hyperactivity disorder: 11-year follow-up in a longitudinal case-control study. Am J Psychiatry. 2010;167(4):409-17.
24. Achenbach TM, Howell C, McConaughy S, Stanger C. Six-year predictors of problems in a national sample: IV. Young adult signs of disturbance. J Am Acad Child Adolesc Psychiatry. 1998;37(7):718-27.
25. Biederman J, Faraone S, Mick E. Age dependent decline of ADHD symptoms revisited: impact of remission definition and symptom subtype. Am J Psychiatry. 2000;157:816-7.
26. Millstein RB, Wilens TE, Biederman J, Spencer TJ. Presenting ADHD symptoms and subtypes in clinically referred adults with ADHD. J Atten Disord. 1997; 2(3):159-66.
27. Wilens T, Biederman J, Faraone S, Martelon M, Westerberg D, Spencer T. Presenting ADHD symptoms, subtypes, and comorbid disorders in clinically referred adults with ADHD. J Clin Psychiatry. 2009;70(11):1557-62.
28. Barkley RA. ADHD and the Nature of Self-Control. Guilford; New York, NY, USA: 1997.
29. Reimherr F, Marchant BK, Strong RE, Hedges DW, Adler L, Spencer TJ, et al. Emotional dysregulation in adult ADHD and response to atomoxetine. Biol Psychiatry. 2005;58(2):125-31.
30. Faraone SV, Doyle AE. The nature and heritability of attention-deficit/ hyperactivity disorder. Child Adolesc Psychiatr Clin N Am. 2001;10(2):299-292ix.47.
31. Faraone SV. Genetics of adult attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004;27:303-21.
32. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, Sklar P. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57(11):1313-23.
33. Wender PH, Wolf LE, Wasserstein J. Adults with ADHD, An overview. Ann N Y Acad Sci. 2001;931:1-16.
34. Sprich S, Biederman J, Crawford MH, Munday E, Faraone SV. Adoptive and biological families of children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry. 2000;39(11):1432-7.
35. Moore J, Fombonne E. Psychopathology in adopted and non adopted children: a clinical sample. Am J Orthopsychiatry. 1999;69(3):403-9.
36. Gilger JW, Pennington BF, DeFries JC. A twin study of the etiology of comorbidity: attention-deficit hyperactivity disorder and dyslexia. J Am Acad Child Adolesc Psychiatry. 1992;31(2):343-8.

37. Sherman DK, Iacono WG, McGue MK. Attention-deficit hyperactivity disorder dimensions: a twin study of inattention and impulsivity–hyperactivity. J Am Acad Child Adolesc Psychiatry. 1997;36(6):745-53.

38. Rietveld MJ, Hudziak JJ, Bartels MvB, CE, Boomsma DI. Heritability of attention problems in children: longitudinal results from a study of twins, age 3 to 12. J Child Psychol Psychiatry. 2004;45(3):577-88.

39. Levy F, Hay DA, McStephen M, Wood C, Waldman I. Attention-deficit hyperactivity disorder: a category or a continuum? Genetic analysis of a large-scale twin study. J Am Acad Child Adolesc Psychiatry. 1997;36(6):737-44.

40. Faraone SV, Biederman J, Monuteaux MC. Toward guidelines for pedigree selection in genetic studies of attention deficit hyperactivity disorder. Genetic epidemiology. 2000;18(1):1-16.

41. Biederman J, Faraone SV, Mick E, Spencer T, Wilens T, Kiely K, et al. High risk for attention deficit hyperactivity disorder among children of parents with childhood onset of the disorder: a pilot study. Am J Psychiatry 1995; -152:431-5.

- Van den Berg SM, Willemser G, de Geus EJ, Boomsma DI. Genetic etiology of stability of attention problems in young adulthood. Am J Med Genet B Neuropsychiatr Genet. 2006;141B(1):55-60.

43. Boomsma DI, Saviouk V, Hottenga JJ, Distel MA, de Moor MH, Vink JM, Geels LM, van Beek JH, Bartels M, de Geus EJ, et al. Genet epidemiol of attention deficit hyperactivity disorder (ADHD index) in adults. PloS one. 2010;5(5):e10621.

44. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn, revised. American Psychiatric Press: Washington, DC 2000.

45. Halperin JM, Schulz KP. Revisiting the role of the prefrontal cortex in the pathophysiology of attention-deficit/ hyperactivity disorder. Psychological bulletin. 2006;132(4):560-81.

46. Halperin JM, Trampush JW, Miller CJ, Marks DJ, Newcorn JH. Neuropsychological outcome in adolescents/young adults with childhood ADHD: profiles of persisters, remitters and controls. Journal of child psychology and psychiatry, and allied disciplines. 2008;49(9):958-66.

47. Kuntsi J, Wood AC, Rijsdijk F, Johnson KA, Andreou P, Albrecht B, Arias Vasquez A, Buitelaar J, McLoughlin G, Rommelse N, et al. Separation of cognitive impairments in attention deficit hyperactivity disorder into two familial factors. Arch Gen Psychiatry. 2010;67(11):1159-67.

48. Li D, Sham PC, Owen MJ, He L. Meta-analysis shows significant association between dopamine system genes and attention deficit hyperactivity disorder (ADHD). Human molecular genetics. 2006;15(14):2276-84.

49. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, Sklar P. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005, 57(11):1313-1323.

50. Kuntsi J, Neale BM, Chen W, Faraone SV, Asherson P. The IMAGE project: methodological issues for the molecular genetic analysis of ADHD. Behav Brain Funct. 2006;2:27.

51. Larsson JO, Larsson H, Lichtenstein P. Genetic and environmental contributions to stability and change of ADHD symptoms between 8 and 13 years of age: a longitudinal twin study. J Am Acad Child Adolesc Psychiatry. 2004;43:1267-75.

52. Johnston C, Mash EJ. Families of children with attention-deficit/hyperactivity disorder: review and recommendations for future research. Clin Child Fam Psychol Rev. 2001;4:183-207.

53. Sonuga-Barke EJS, Daly D, Thompson M. Parent based therapies for preschool attention deficit/hyperactivity disorder: a randomized controlled trial with a community sample. J Am Acad Child Adolesc Psychiatry. 2001;40:402-8.

54. Gardner FEM. The quality of joint activity between mothers and their children with behaviour problems. J Child Psychol Psychiatry. 1994;35:935-48.

55. Johnston C, Mash EJ. Families of children with attention-deficit/hyperactivity disorder: review and recommendations for future research. Clin Child Fam Psychol Rev. 2001;4:183-207.

56. Befera MS, Barkley RA. Hyperactive and normal girls and boys: mother-child interaction, parent psychiatric status and child psychopathology. J Child Psychol Psychiatry. 1985;26:439-52.

57. Danforth JS, Barkley RA, Stokes TF. Observations of parent-child interactions with hyperactive children: research and clinical implications. Clin Psychol Rev. 1991;11:703-27.

58. Gomez R, Sanson AV. Mother-child interactions and noncompliance in hyperactive boys with and without conduct problems. J Child Psychol Psychiatry. 1994;35:477-90.

59. Befera MS, Barkley RA. Hyperactive and normal girls and boys: mother-child interaction, parent psychiatric status and child psychopathology. J Child Psychol Psychiatry. 1985;26:439-52.

60. Boris M, Mandel FS. Foods and additives are common causes of the attention deficit hyperactive disorder in children. Ann Allergy Asthma Immunol. 1994;72:462-8.

61. APA: American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders. Washington DC , 4 1994.

62. Faraone SV, Biederman J, Monuteaux MC. Toward guidelines for pedigree selection in genetic studies.
of attention deficit hyperactivity disorder. Genetic epidemiology. 2000;18(1):1-16.
63. Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Brugué M, Carpentier PJ, et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry. 2010;10:67.
64. NICE: Attention Deficit Hyperactivity Disorder: The NICE guideline on diagnosis and management of ADHD in children, young people and adults The British Psychological Society and The Royal College of Psychiatrists 2008.
65. Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Dopfner M, Faraone SV, Rothenberger A, et al: Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry. 2006;15(8):476-95.
66. Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, Dunkel S, Dougherty M, Aleardi M, Spencer T. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006;59(9):829-35.
67. Rosler M, Fischer R, Ammer R, Ose C, Retz W. A randomized, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci. 2009;259(2):120-9.
68. Kooij JJS, Burger H, Boonstra AM, van der Linden PD, Kalma LE, Buitelaar JK. Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychol Med. 2004;34(6):973-82.
69. Bouffard R, Hechtman L, Minde K, Iaboni-Kassab F. The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Can J Psychiatry. 2003;48(8):546-54.
70. Wilens TE, Spencer TJ: The stimulants revisited. Child Adolesc Psychiatr Clin. 2000;9(3):573-603, viii.

Cite this article as: Gill A, Bhatt A. Attention deficit hyperactivity disorder: a short review. Int J Adv Med 2016;3:446-51.